Pathological laughing and crying: Epidemiology, pathophysiology and treatment

CNS Drugs

Volumn 22, Issue 7, 2008, Pages 531-545

  Wortzel, Hal S ^a,b,c   Oster, Timothy J ^c   Anderson, C Alan ^b,c   Arciniegas, David B ^a,b,c  

^a HealthONE Spalding Rehabilitation Hospital   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Amantadine, therapeutic use; Amitriptyline, therapeutic use; Citalopram, therapeutic use; Dextromethorphan quinidine, therapeutic use; Dopamine receptor agonists, therapeutic use; Emotional lability, epidemiology; Emotional lability, pathogenesis

Indexed keywords

ALPRENOLOL; AMANTADINE; AMITRIPTYLINE; AMPHETAMINE; CARBIDOPA; CARVEDILOL; CHLORPHENIRAMINE; CITALOPRAM; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DOPAMINE; ESCITALOPRAM; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; LAMOTRIGINE; LEVODOPA; MIRTAZAPINE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; QUINIDINE; REBOXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VENLAFAXINE;

AFFECT; CLINICAL EXAMINATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG METABOLISM; FATIGUE; HEADACHE; HUMAN; INCIDENCE; LIMBIC SYSTEM; LOW DRUG DOSE; MOOD; NAUSEA; NEUROANATOMY; NEUROCHEMISTRY; NEUROPATHOLOGY; NOMENCLATURE; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOMNOLENCE; SYNDROME DELINEATION; UNSPECIFIED SIDE EFFECT;

AFFECT; CRYING; HUMANS; LAUGHTER; NERVOUS SYSTEM DISEASES; NEUROANATOMY; NEUROCHEMISTRY; NEUROTRANSMITTER AGENTS;

EID: 44949201851     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822070-00001     Document Type: Review

References (110)

1. Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to valuation and treatment. Semin Clin Neuropsychiatry 2000 Oct; 5 (4): 290-306
2. Wilson SAK. Some problems in neurology: no. II. Pathological laughing and crying. J Neurol Psychopathol 1924; 4 (16): 299-333
3. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985; 312 (23): 1480-2
4. Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006 Jun; 11 (6): 1-7
5. Rabins PV, Arciniegas DB. Pathophysiology of involuntary emotional expression disorder. CNS Spectr 2007 Apr; 12 (4 Suppl. 5): 17-22
6. Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc 2006 Nov; 81 (11): 1482-6
7. Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain 2001 Sep; 124 (Pt 9): 1708-19
8. Calvert T, Knapp P, House A. Psychological associations with emotionalism after stroke. J Neurol Neurosurg Psychiatry 1998 Dec; 65 (6): 928-9
9. Brooks BR. Involuntary emotional expression disorder: treating the untreated. CNS Spectr 2007 Apr; 12 (4 Suppl. 5): 23-7
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
11. Arciniegas DB. A clinical overview of pseudobulbar affect. Am J Geriatr Pharmacother 2005; 3 Suppl. A: 4-8
12. Feinstein A, Feinstein K, Gray T, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997 Sep; 54 (9): 1116-21
13. Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005; 17 (4): 447-54
14. Zeilig G, Drubach DA, Katz-Zeilig M, et al. Pathological laughter and crying in patients with closed traumatic brain injury. Brain Inj 1996; 10 (8): 591-7
15. Tateno A, Jorge RE, Robinson RG. Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004; 16 (4): 426-34
16. House A, Dennis M, Molyneux A, et al. Emotionalism after stroke. BMJ 1989 Apr; 298 (6679): 991-4
17. Kim JS. Pathological laughter and crying in unilateral stroke. Stroke 1997 Nov; 28 (11): 2321
18. Robinson RG, Parikh RM, Lipsey JR, et al. Pathological laugh-ing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993 Feb; 150 (2): 286-93
19. Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989 Aug; 80 (2): 114-7
20. Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol 1985; 232 (5): 295-300
21. Tariot PN, Mack JL, Patterson MB, et al. The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry 1995 Sep; 152 (9): 1349-57
22. Haupt M. Emotional lability, intrusiveness, and catastrophic reactions. Int Psychogeriatr 1996; 8 Suppl. 3: 409-14
23. Starkstein SE, Migliorelli R, Teson A, et al. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1995 Jul; 59 (1): 55-60
24. Loeb C, Poggio GF. Neural substrates of memory, affective functions, and conscious experience. Adv Anat Embryol Cell Biol 2002; 166: 1-111
25. Damasio AR, Grabowski TJ, Bechara A, et al. Subcortical and cortical brain activity during the feeling of self-generated emotions. Nat Neurosci 2000 Oct; 3 (10): 1049-56
26. Lane RD, Reiman EM, Bradley MM, et al. Neuroanatomical correlates of pleasant and unpleasant emotion. Neuropsychologia 1997 Nov; 35 (11): 1437-44
27. Lane RD, Reiman EM, Ahern GL, et al. Neuroanatomical correlates of happiness, sadness, and disgust. Am J Psychiatry 1997 Jul; 154 (7): 926-33
28. Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion perception: I. The neural basis of normal emotion perception. Biol Psychiatry 2003 Sep 1; 54 (5): 504-14
29. Arciniegas DB, Lauterbach EC, Anderson KE, et al. The differential diagnosis of pseudobulbar affect (PBA): distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting. CNS Spectr 2005 May; 10 (5): 1-14
30. Schmahmann JD, Caplan D. Cognition, emotion and the cerebellum. Brain 2006 Feb; 129 (Pt 2): 290-2
31. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998 Apr; 121 (Pt 4): 561-79
32. Schmahmann JD. An emerging concept: the cerebellar contribution to higher function. Arch Neurol 1991 Nov; 48 (11): 1178-87
33. Parvizi J, Schiffer R. Exaggerated crying and tremor with a cerebellar cyst. J Neuropsychiatry Clin Neurosci 2007; 19 (2): 187-90
34. Parvizi J, Joseph J, Press DZ, et al. Pathological laughter and crying in patients with multiple system atrophy-cerebellar type. Mov Disord 2007 Apr 30; 22 (6): 798-803
35. Plutchik R. A general psychoevolutionary theory of emotion. In: Plutchik R, Kellerman H, editors. Emotion: theory, research, and experience. Vol. 1. Theories of emotion. New York: Academic, 1980: 3-33
36. Ekman P. Emotion in the human face. New York: Cambridge University Press, 1982
37. Phan KL, Wager T, Taylor SF, et al. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage 2002 Jun; 16 (2): 331-48
38. Sackeim HA, Greenberg MS, Weiman AL, et al. Hemispheric asymmetry in the expression of positive and negative emotions. Neurologic evidence. Arch Neurol 1982 Apr; 39 (4): 210-8
39. Andersen G, Ingeman-Nielsen M, Vestergaard K, et al. Pathoanatomic correlation between poststroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke 1994 May; 25 (5): 1050-2
40. Derex L, Ostrowsky K, Nighoghossian N, et al. Severe pathological crying after left anterior choroidal artery infarct: reversibility with paroxetine treatment. Stroke 1997 Jul; 28 (7): 1464-6
41. Murai T, Barthel H, Berrouschot J, et al. Neuroimaging of serotonin transporters in post-stroke pathological crying. Psychiatry Res 2003 Jul 30; 123 (3): 207-11
42. Møller M, Andersen G, Gjedde A. Serotonin 5HT1A receptor availability and pathological crying after stroke. Acta Neurol Scand 2007 Aug; 116 (2): 83-90
43. Møller M, Andersen G. Inhibition of selective noradrenergic reuptake as treatment of pathological laughter. J Clin Psychopharmacol 2007 Feb; 27 (1): 108-10
44. Lauterbach EC, Schweri MM. Amelioration of pseudobulbar affect by fluoxetine: possible alteration of dopamine-related pathophysiology by a selective serotonin reuptake inhibitor. J Clin Psychopharmacol 1991 Dec; 11 (6): 392-3
45. Evans RW, Gualtieri CT, Patterson D. Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis 1987 Feb; 175 (2): 106-10
46. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004 Oct 26; 63 (8): 1364-70
47. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006 May; 59 (5): 780-7
48. Kim SW, Shin IS, Kim JM, et al. Mirtazapine treatment for pathological laughing and crying after stroke. Clin Neuropharmacol 2005 Sep; 28 (5): 249-51
49. Linner L, Wiker C, Arborelius L, et al. Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain. J Neural Transm 2004 Feb; 111 (2): 127-39
50. Taylor MJ, Freemantle N, Geddes JR, et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006 Nov; 63 (11): 1217-23
51. Sackeim HA, Roose SP, Burt T. Optimal length of antidepressant trials in late-life depression. J Clin Psychopharmacol 2005 Aug; 25 (4 Suppl. 1): S34-7
52. Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005 Dec; 26 (12): 631-8
53. Donati RJ, Rasenick MM. G protein signaling and the molecular basis of antidepressant action. Life Sci 2003 May 23; 73 (1): 1-17
54. Pearce JM. A note on gelastic epilepsy. Eur Neurol 2004; 52 (3): 172-4
55. Chahine LM, Chemali Z. Du rire aux larmes: pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine. Epilepsy Behav 2006 May; 8 (3): 610-5
56. House AO, Hackett ML, Anderson CS, et al. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database Syst Rev 2004; (2): CD003690
57. Andersen G, Stylsvig M, Sunde N. Citalopram treatment of traumatic brain damage in a 6-year-old boy. J Neurotrauma 1999 Apr; 16 (4): 341-4
58. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993 Oct 2; 342 (8875): 837-9
59. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996 Dec; 19 (6): 532-5
60. Muller U, Murai T, Bauer-Wittmund T, et al. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999 Oct; 13 (10): 805-11
61. Tsai WC, Lai JS, Wang TG. Treatment of emotionalism with fluoxetine during rehabilitation. Scand J Rehabil Med 1998 Sep; 30 (3): 145-9
62. Burns A, Russell E, Stratton-Powell H, et al. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999 Aug; 14 (8): 681-5
63. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005 Jun; 66 (6): 708-16
64. Mukand J, Kaplan M, Senno RG, et al. Pathological crying and laughing: treatment with sertraline. Arch Phys Med Rehabil 1996 Dec; 77 (12): 1309-11
65. Nahas Z, Arlinghaus KA, Kotrla KJ, et al. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998; 10 (4): 453-5
66. Benedek DM, Peterson KA. Sertraline for treatment of pathological crying. Am J Psychiatry 1995 Jun; 152 (6): 953-4
67. Seliger GM, Hornstein A. Serotonin, fluoxetine, and pseudobulbar affect [letter]. Neurology 1989 Oct; 39 (10): 1400
68. Seliger GM, Hornstein A, Flax J, et al. Fluoxetine improves emotional incontinence. Brain Inj 1992 May; 6 (3): 267-70
69. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr Scand 1998 Dec; 98 (6): 455-8
70. Sloan RL, Brown KW, Pentland B. Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj 1992 Jul; 6 (4): 315-9
71. Jeret JS. Treatment of poststroke pathological crying. Stroke 1997 Nov; 28 (11): 2321-2
72. Panzer MJ, Mellow AM. Antidepressant treatment of pathologic laughing or crying in elderly stroke patients. J Geriatr Psychiatry Neurol 1992 Oct; 5 (4): 195-9
73. Schmitt JA, Kruizinga MJ, Riedel WJ. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001 Sep; 15 (3): 173-9
74. Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004 Apr; 172 (4): 400-8
75. Ivan TM, Franco K. Poststroke pathological laughing and crying. Am J Psychiatry 1994 Feb; 151 (2): 290-1
76. Schiffer RB, Cash J, Herndon RM. Treatment of emotional lability with low-dosage tricyclic antidepressants. Psychosomatics 1983 Dec; 24 (12): 1094-6
77. Szczudlik A, Slowik A, Tomik B. The effect of amitriptyline on the pathological crying and other pseudobulbar signs [in Polish]. Neurol Neurochir Pol 1995 Sep; 29 (5): 663-74
78. Allman P. Drug treatment of emotionalism following brain damage. J R Soc Med 1992 Jul; 85 (7): 423-4
79. de Oliveira-Souza R, de Figueiredo WM, Andreiuolo PA. Pathological crying and unilateral pontine infarction [in Portuguese]. Arq Neuropsiquiatr 1995 Sep; 53 (3-B): 680-9
80. Lawson IR, MacLeod RD. The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. Br J Psychiatry 1969 Mar; 115 (520): 281-5
81. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17-25
82. Rosenberg C, Lauritzen L, Brix J, et al. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a Danish multicentre trial in general practice. Psychopharmacol Bull 2007; 40 (1): 63-73
83. van Laar MW, van Willigenburg AP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995 Feb; 15 (1): 30-40
84. Jiang W, Davidson JR. Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005 Nov; 150 (5): 871-81
85. Murray JB. Cardiac disorders and antidepressant medications. J Psychol 2000 Mar; 134 (2): 162-8
86. Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J 2000 Oct; 140 (4 Suppl.): 84-8
87. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006 Dec; 51 (14): 923-9
88. Smith AG, Montealegre-Orjuela M, Douglas JE, et al. Venlafaxine for pathological crying after stroke. J Clin Psychiatry 2003 Jun; 64 (6): 731-2
89. Ramasubbu R. Lamotrigine treatment for post-stroke pathological laughing and crying. Clin Neuropharmacol 2003 Sep; 26 (5): 233-5
90. Wolf JK, Santana HB, Thorpy M. Treatment of "emotional incontinence" with levodopa. Neurology 1979 Oct; 29 (10): 1435-6
91. Udaka F, Yamao S, Nagata H, et al. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984 Oct; 41 (10): 1095-6
92. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001 Feb; 3 (1): 22-7
93. Flockhart DA. Cytochrome P450 drug-interaction table. Division of Clinical Pharmacology, Indiana University-Purdue University Indianapolis, 2007 October 29 [online]. Available from: URL: http://medicine.iupui.edu/flockhart/ table.htm [Accessed 2007 Nov 22]
94. Pucci E, Branas P, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007; (1): CD002818
95. Taus C, Giuliani G, Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2003; (2): CD002818
96. Drake Jr ME, Pakalnis A, Denio LS, et al. Amantadine hydrochloride for refractory generalized epilepsy in adults. Acta Neurol Belg 1991; 91 (3): 159-64
97. Shields WD, Lake JL, Chugani HT. Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients. Neurology 1985 Apr; 35 (4): 579-81
98. Shahar EM, Brand N. Effect of add-on amantadine therapy for refractory absence epilepsy. J Pediatr 1992 Nov; 121 (5 Pt 1): 819-21
99. Reis J, John D, Heimeroth A, et al. Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology 2006 Dec; 31 (12): 2758-66
100. Mizoguchi K, Yokoo H, Yoshida M, et al. Amantadine increases the extracellular dopamine levels in the striatum by reuptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res 1994 Oct 31; 662 (1-2): 255-8
101. Jackisch R, Link T, Neufang B, et al. Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 1992 Nov; 320: 21-42
102. Peeters M, Romieu P, Maurice T, et al. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004 Apr; 19 (8): 2212-20
103. Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989 Dec; 10 (12): 501-7
104. Klein M, Paturzo JJ, Musacchio JM. The effect of prototypic sigma ligands on the binding of [3H]dextromethorphan to guinea pig brain. Neurosci Lett 1989 Feb 13; 97 (1-2): 175-80
105. Yamamoto H, Yamamoto T, Sagi N, et al. Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site. J Neurosci 1995 Jan; 15 (1 Pt 2): 731-6
106. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005 Mar; 97 (3): 317-36
107. Bermack JE, Debonnel G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 2005 Jan; 55 (1): 37-44
108. Bermack JE, Debonnel G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br J Pharmacol 2001 Oct; 134 (3): 691-9
109. Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996 Jun 20; 307 (1): 117-9
110. Dhir A, Kulkarni SK. Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. Neurosci Lett 2007 Jun 15; 420 (3): 204-8